Communiqués Bayer AG

Actions

BAYN

DE000BAY0017

Produits pharmaceutiques

Marché Fermé - Xetra Autres places de cotation 17:36:43 16/06/2026			Après clôture 20:57:59
36,01 ^EUR	-0,83%		35,90	-0,31%

06:32	"Agent orange": une action contre Bayer-Monsant examinée en France	AW
15/06	Bayer obtient le feu vert de la FDA pour l'Ambelvist, un agent de contraste pour l'IRM permettant de détecter les lésions à vascularisation anormale	CI

Communiqués

16:02	Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief	BU
15/06	Bayer : Expands Open Innovation Network in China with New Hub in Shandong Province	PU
15/06	Bayer : low-dose MRI contrast agent approved in U.S.	PU
15/06	Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions	BU
10/06	Dr. Jost Reinhard Appointed President of Bayer's Radiology Business	AQ
10/06	Bayer : European Medicines Agency confirms asundexian marketing authorization application for assessment in secondary prevention of ischemic stroke	PU
09/06	Bayer : Jana Marlen Ackermann to be new Head of Investor Relations at Bayer	PU
09/06	Dr. Jost Reinhard Appointed President of Bayer’s Radiology Business	BU
09/06	Bayer : Announces Advancement in Cardiovascular Health Assessment with Saudi Heart Association's recent publication on Early Detection of Subclinical Atherosclerosis in Clinical Practice	PU
08/06	Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth	BU
05/06	Bayer : Finerenone significantly reduced the risk of kidney disease progression and cardiovascular outcomes in broad patient populations with CKD	PU
05/06	Bayer : finerenone significantly reduced kidney function decline and a composite of cardiovascular-kidney outcomes versus placebo in patients with non-diabetic chronic kidney disease	PU
05/06	Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease	BU
02/06	Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026	BU
30/05	ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial	BU
22/05	Bayer : Kerendia™ approved in China for new indication in adult patients with heart failure with LVEF ≥40%	PU
21/05	ASCO 2026: Bayer to Present New Data Across Oncology Portfolio	BU
21/05	Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease	BU
19/05	Bayer : New drug applications for asundexian accepted by U.S. Food and Drug Administration under Priority Review and by Japan’s Ministry of Health, Labour and Welfare	PU
19/05	Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack	BU
18/05	U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer	BU
18/05	Bayer : FDA grants sevabertinib Priority Review as a first-line treatment for patients with HER2-mutant non-small cell lung cancer	PU
15/05	AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer	BU
15/05	Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement	BU
13/05	Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities	BU